Delafloxacin-Capped Gold Nanoparticles (DFX-AuNPs): An Effective Antibacterial Nano-Formulation of Fluoroquinolone Antibiotic

Overview

Journal Materials (Basel)

Publisher MDPI

Date 2022 Aug 26

PMID 36013845

Authors

Amr Selim Abu Lila

Bader Huwaimel

Ahmed Alobaida

Talib Hussain

Zeeshan Rafi

Khalid Mehmood

Marwa H Abdallah

Turki Al Hagbani

Syed Mohd Danish Rizvi

Afrasim Moin

Abobakr F Ahmed

Affiliations

Soon will be listed here.

Abstract

New antibiotics are seen as 'drugs of last resort' against virulent bacteria. However, development of resistance towards new antibiotics with time is a universal fact. Delafloxacin (DFX) is a new fluoroquinolone antibiotic that differs from existing fluoroquinolones by the lack of a protonatable substituent, which gives the molecule a weakly acidic nature, affording it higher antibacterial activity under an acidic environment. Furthermore, antibiotic-functionalized metallic nanoparticles have been recently emerged as a feasible platform for conquering bacterial resistance. In the present study, therefore, we aimed at preparing DFX-gold nano-formulations to increase the antibacterial potential of DFX. To synthesize DFX-capped gold nanoparticles (DFX-AuNPs), DFX was used as a reducing and stabilizing/encapsulating agent. Various analytical techniques such as UV-visible spectroscopy, TEM, DLS, FTIR and zeta potential analysis were applied to determine the properties of the synthesized DFX-AuNPs. The synthesized DFX-AuNPs revealed a distinct surface plasmon resonance (SPR) band at 530 nm and an average size of 16 nm as manifested by TEM analysis. In addition, Zeta potential results (-19 mV) confirmed the stability of the synthesized DFX-AuNPs. Furthermore, FTIR analysis demonstrated that DFX was adsorbed onto the surface of AuNPs via strong interaction between AuNPs and DFX. Most importantly, comparative antibacterial analysis of DFX alone and DFX-AuNPs against Gram-negative ( and ) and Gram-positive ( and ) verified the superior antibacterial activity of DFX-AuNPs against the tested microorganisms. To sum up, DFX gold nano-formulations can offer a promising possible solution, even at a lower antibiotic dose, to combat pathogenic bacteria.

Citing Articles

Correlation Analysis Between Multi-Drug Resistance Phenotype and Virulence Factor Expression of Clinical .

Xu W, Zhou R, Pan J, Liu Z, Huang X, Lin Y Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852165 PMC: 11763688. DOI: 10.3390/cimb47010050.

Comparative efficacy of difloxacin and nano-emulsion difloxacin as antibacterial agents against in chickenss.

Ashosh M, El-Abasy M, El-Borady O, Elkhaiat I, Ismail M Open Vet J. 2024; 14(1):449-458.

PMID: 38633146 PMC: 11018397. DOI: 10.5455/OVJ.2024.v14.i1.41.

Review of Advances in Coating and Functionalization of Gold Nanoparticles: From Theory to Biomedical Application.

Arcos Rosero W, Bueno Barbezan A, de Souza C, Rostelato M Pharmaceutics. 2024; 16(2).

PMID: 38399309 PMC: 10892584. DOI: 10.3390/pharmaceutics16020255.

[In vitro activity of delafloxacin against clinical isolates of carbapenem-resistant Pseudomonas aeruginosa in a stage prior to the clinical use of this drug].

Garcia-Rivera C, Navarro M, Parra M, Sanchez Bautista A, Gomez I, Ventero M Rev Esp Quimioter. 2023; 37(1):104-105.

PMID: 38140799 PMC: 10874670. DOI: 10.37201/req/080.2023.

A potential strategy against clinical carbapenem-resistant Enterobacteriaceae: antimicrobial activity study of sweetener-decorated gold nanoparticles in vitro and in vivo.

Liu H, Huang Z, Chen H, Zhang Y, Yu P, Hu P J Nanobiotechnology. 2023; 21(1):409.

PMID: 37932843 PMC: 10626710. DOI: 10.1186/s12951-023-02149-x.

References

Okkeh M, Bloise N, Restivo E, De Vita L, Pallavicini P, Visai L . Gold Nanoparticles: Can They Be the Next Magic Bullet for Multidrug-Resistant Bacteria?. Nanomaterials (Basel). 2021; 11(2). PMC: 7911621. DOI: 10.3390/nano11020312. View

Rasmussen M, Pedersen J, Marie R . Size and surface charge characterization of nanoparticles with a salt gradient. Nat Commun. 2020; 11(1):2337. PMC: 7214416. DOI: 10.1038/s41467-020-15889-3. View

Jacoby G . Mechanisms of resistance to quinolones. Clin Infect Dis. 2005; 41 Suppl 2:S120-6. DOI: 10.1086/428052. View

Tulkens P, Van Bambeke F, Zinner S . Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Clin Infect Dis. 2019; 68(Suppl 3):S213-S222. PMC: 6452001. DOI: 10.1093/cid/ciy1079. View

Kato H, Nakamura A, Takahashi K, Kinugasa S . Accurate Size and Size-Distribution Determination of Polystyrene Latex Nanoparticles in Aqueous Medium Using Dynamic Light Scattering and Asymmetrical Flow Field Flow Fractionation with Multi-Angle Light Scattering. Nanomaterials (Basel). 2017; 2(1):15-30. PMC: 5327882. DOI: 10.3390/nano2010015. View

Soliman W, Khan S, Danish Rizvi S, Moin A, Elsewedy H, AbuLila A . Therapeutic Applications of Biostable Silver Nanoparticles Synthesized Using Peel Extract of : Antibacterial and Anticancer Activities. Nanomaterials (Basel). 2020; 10(10). PMC: 7600797. DOI: 10.3390/nano10101954. View

Maincent P, Le Verge R, Sado P, Couvreur P, Devissaguet J . Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J Pharm Sci. 1986; 75(10):955-8. DOI: 10.1002/jps.2600751009. View

Barzan G, Rocchetti L, Portesi C, Pellegrino F, Taglietti A, Rossi A . Surface Minimal Bactericidal Concentration: A comparative study of active glasses functionalized with different-sized silver nanoparticles. Colloids Surf B Biointerfaces. 2021; 204:111800. DOI: 10.1016/j.colsurfb.2021.111800. View

Rajendiran K, Zhao Z, Pei D, Fu A . Antimicrobial Activity and Mechanism of Functionalized Quantum Dots. Polymers (Basel). 2019; 11(10). PMC: 6835343. DOI: 10.3390/polym11101670. View

10.

Spirescu V, Chircov C, Grumezescu A, Andronescu E . Polymeric Nanoparticles for Antimicrobial Therapies: An Up-To-Date Overview. Polymers (Basel). 2021; 13(5). PMC: 7956825. DOI: 10.3390/polym13050724. View

11.

Sondi I, Salopek-Sondi B . Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci. 2004; 275(1):177-82. DOI: 10.1016/j.jcis.2004.02.012. View

12.

Ferreira M, Ogren M, Dias J, Silva M, Gil S, Tavares L . Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance. Molecules. 2021; 26(7). PMC: 8038399. DOI: 10.3390/molecules26072047. View

13.

Neuhauser M, Weinstein R, Rydman R, Danziger L, Karam G, Quinn J . Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003; 289(7):885-8. DOI: 10.1001/jama.289.7.885. View

14.

Moin A, Wani S, Osmani R, Lila A, Khafagy E, Arab H . Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer. Drug Deliv. 2021; 28(1):1626-1636. PMC: 8330732. DOI: 10.1080/10717544.2021.1958106. View

15.

Winnicka K, Wroblewska M, Wieczorek P, Sacha P, Tryniszewska E . The effect of PAMAM dendrimers on the antibacterial activity of antibiotics with different water solubility. Molecules. 2013; 18(7):8607-17. PMC: 6269725. DOI: 10.3390/molecules18078607. View

16.

Djalali R, Chen Y, Matsui H . Au nanowire fabrication from sequenced histidine-rich peptide. J Am Chem Soc. 2002; 124(46):13660-1. DOI: 10.1021/ja028261r. View

17.

Couvreur P, Tulkens P, Roland M, Trouet A, SPEISER P . Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett. 1977; 84(2):323-6. DOI: 10.1016/0014-5793(77)80717-5. View

18.

Jorgensen S, Mercuro N, Davis S, Rybak M . Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties. Infect Dis Ther. 2018; 7(2):197-217. PMC: 5986682. DOI: 10.1007/s40121-018-0198-x. View

19.

Mitscher L . Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev. 2005; 105(2):559-92. DOI: 10.1021/cr030101q. View

20.

Emmerson A, Jones A . The quinolones: decades of development and use. J Antimicrob Chemother. 2003; 51 Suppl 1:13-20. DOI: 10.1093/jac/dkg208. View